Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adropin and Irisin as Potential Patentable Biomarkers in Metabolic-Associated Fatty Liver Disease: Current Evidence and Future Directions.

Recent patents on biotechnology·2026
Same author

Pharmacokinetic, docking, and DFT analyses reveal Moringa oleifera phytochemicals as inhibitors of HIF-1α/VEGF/GLUT1 signaling pathway in breast cancer.

Scientific reports·2025
Same author

Advancing nanotheranostics for neuro-immunological disorders: current status and future prospects.

Neuroscience·2025
Same author

Exosome-based therapeutics: Advancing drug delivery for neurodegenerative diseases.

Molecular and cellular neurosciences·2025
Same author

Emergence of a Novel Dengue Virus Serotype-2 Genotype IV Lineage III Strain and Displacement of Dengue Virus Serotype-1 in Central India (2019-2023).

Viruses·2025
Same author

Exploring the link between parvovirus B19 and encephalitis: a systematic review and comprehensive meta-analysis of molecular and serological evidence.

Virology journal·2025

Related Experiment Video

Updated: Jun 5, 2026

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Antiangiogenic therapy using nanotechnological-based delivery system.

Jagat R Kanwar1, Ganesh Mahidhara, Rupinder K Kanwar

  • 1Laboratory of Immunology and Molecular Biomedical Research (LIMBR), Centre for Biotechnology and Interdisciplinary Biosciences (BioDeakin), Institute for Technology Research and Innovation (ITRI), Deakin University, Waurn Ponds, VIC 3217, Australia. jagat.kanwar@deakin.edu.au

Drug Discovery Today
|January 26, 2011
PubMed
Summary

Combinatorial cancer therapy using anti-angiogenic and apoptosis-inducing biomolecules shows promise. Nanotechnology enhances delivery of these agents, improving cancer stem cell treatment and therapeutic outcomes.

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Related Experiment Videos

Last Updated: Jun 5, 2026

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Area of Science:

  • Oncology
  • Biotechnology
  • Nanomedicine

Background:

  • Combinatorial therapy targeting angiogenesis and cancer stem cell apoptosis is a leading strategy for cancer treatment.
  • There is growing interest in utilizing anti-apoptotic and anti-angiogenic biomolecules for cancer therapy.
  • These biomolecules include microRNAs, small interfering RNAs, inhibitor of apoptosis protein-binding peptides, Von Hippel-Lindau tumor suppressors, and aptamers.

Purpose of the Study:

  • To review the potential of anti-apoptotic and anti-angiogenic biomolecules in anticancer therapy.
  • To explore the role of nanotechnology in enhancing the delivery and efficacy of these therapeutic agents.

Main Methods:

  • Review of current literature on cancer treatment strategies.
  • Analysis of nanotechnology-based approaches for drug delivery.
  • Examination of RNA-carrying cationic cell-penetrating peptides for enhanced cellular uptake.

Main Results:

  • Nanotechnology, specifically RNA-carrying cationic cell-penetrating peptides, can protect biomolecules from enzymatic digestion.
  • These nanocarriers enhance the cellular internalization of therapeutic biomolecules.
  • This approach holds potential for improved anticancer therapy by targeting angiogenesis and cancer stem cells.

Conclusions:

  • The combination of anti-angiogenic and apoptosis-inducing strategies is highly recommended for cancer treatment.
  • Nanotechnology offers a viable method for the effective delivery of therapeutic biomolecules.
  • Exploiting nanotechnology with cell-penetrating peptides can overcome challenges in enzymatic degradation and cellular uptake, paving the way for advanced cancer therapies.